Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiangiogenic tumor therapy.
Davis DW, McConkey DJ, Zhang W, Herbst RS. Davis DW, et al. Among authors: herbst rs. Biotechniques. 2003 May;34(5):1048-50, 1052, 1054 passim. doi: 10.2144/03345dd01. Biotechniques. 2003. PMID: 12765031 Free article. Review. No abstract available.
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Herbst RS, et al. J Clin Oncol. 2002 Sep 15;20(18):3804-14. doi: 10.1200/JCO.2002.05.102. J Clin Oncol. 2002. PMID: 12228200 Clinical Trial.
Angiogenesis, metastasis, and lung cancer. An overview.
Onn A, Herbst RS. Onn A, et al. Among authors: herbst rs. Methods Mol Med. 2003;74:329-48. doi: 10.1385/1-59259-323-2:329. Methods Mol Med. 2003. PMID: 12415706 Review. No abstract available.
Angiogenesis as a target for cancer therapy.
Kaban K, Herbst RS. Kaban K, et al. Among authors: herbst rs. Hematol Oncol Clin North Am. 2002 Oct;16(5):1125-71. doi: 10.1016/s0889-8588(02)00047-3. Hematol Oncol Clin North Am. 2002. PMID: 12512387 Review.
Surrogate markers in antiangiogenesis clinical trials.
Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Davis DW, et al. Among authors: herbst rs. Br J Cancer. 2003 Jul 7;89(1):8-14. doi: 10.1038/sj.bjc.6601035. Br J Cancer. 2003. PMID: 12838293 Free PMC article. Review.
A phase I surrogate endpoint study of SU6668 in patients with solid tumors.
Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL. Xiong HQ, et al. Invest New Drugs. 2004 Nov;22(4):459-66. doi: 10.1023/B:DRUG.0000036688.96453.8d. Invest New Drugs. 2004. PMID: 15292716 Clinical Trial.
432 results